Good morning :)
Place Order
Add to Watchlist

Ambalal Sarabhai Enterprises Ltd

AMBALALSA

Ambalal Sarabhai Enterprises Ltd

AMBALALSA
Health CarePharmaceuticals
SmallcapWith a market cap of ₹428 cr, stock is ranked 1,919
High RiskStock is 4.73x as volatile as Nifty
56.001.61% (+0.89)
56.001.61% (+0.89)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹428 cr, stock is ranked 1,919
High RiskStock is 4.73x as volatile as Nifty
Scorecard

Performance

Avg

Price return has been average, nothing exciting

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

Avg

Average profitability - not good, not bad

Entry point

Avg

The stock is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹428 cr, stock is ranked 1,919
High RiskStock is 4.73x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
32.183.13
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
49.886.300.52%

Forecast & Ratings

Detailed Forecast 
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Ambalal Sarabhai Enterprises Limited is a manufacturer of formulations. It markets specialty pharmaceutical products under its three sub-divisions: oncology, infertility and uro-gynaec.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Lower than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 2.88%, vs industry avg of 9.03%

Decreasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 0.07% to 0.05%

Lower than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 5.97%, vs industry avg of 15.28%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue226.99140.37150.24159.60157.89203.33245.19182.77183.94194.38
Raw Materialssubtract71.2577.0671.3390.2881.5198.39114.07105.2498.61172.66
Power & Fuel Costsubtract3.672.682.843.222.712.863.644.205.48
Employee Costsubtract31.2928.7126.6726.0227.0628.1725.2722.0524.59
Selling & Administrative Expensessubtract19.8818.9818.3518.3417.1519.1416.6719.6220.70
Operating & Other expensessubtract18.5817.5217.568.138.3516.6326.9811.0218.24
Depreciation/Amortizationsubtract16.544.272.122.102.572.412.322.763.573.37
Interest & Other Itemssubtract4.104.773.413.293.613.202.042.716.094.06
Taxes & Other Itemssubtract13.544.606.693.970.883.186.983.720.980.97
EPS6.28-2.380.170.551.833.836.161.490.741.74
DPS0.000.000.000.000.000.000.000.000.000.00
Payout ratio0.000.000.000.000.000.000.000.000.000.00

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Ambalal Sarabhai Enterprises Ltd75.473.13
Sun Pharmaceutical Industries Ltd44.306.320.76%
Cipla Ltd29.394.520.87%
Torrent Pharmaceuticals Ltd63.3915.310.90%

Price Comparison

Compare AMBALALSA with any stock or ETF
Compare AMBALALSA with any stock or ETF
AMBALALSA
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Increased Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has increased by 1.68%

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding31.35%0.00%0.01%0.00%68.65%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep0.00%0.00%0.00%0.00%0.00%0.00%

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

AMBALALSA has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

Dividends

Hmm, looks like data is unavailable here. Please come back after some time
News & Opinions
Earnings
Ambalal Sarabhai Enterprises consolidated net profit rises 142.59% in the September 2024 quarter

Net profit of Ambalal Sarabhai Enterprises rose 142.59% to Rs 2.62 crore in the quarter ended September 2024 as against Rs 1.08 crore during the previous quarter ended September 2023. Sales rose 11.72% to Rs 44.70 crore in the quarter ended September 2024 as against Rs 40.01 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales44.7040.01 12 OPM %5.682.55 - PBDT4.122.94 40 PBT3.111.81 72 NP2.621.08 143 Powered by Capital Market - Live

2 days agoCapital Market - Live
Corporate
Ambalal Sarabhai Enterprises to convene board meeting

Ambalal Sarabhai Enterprises will hold a meeting of the Board of Directors of the Company on 12 November 2024Powered by Capital Market - Live

1 week agoCapital Market - Live
Earnings
Ambalal Sarabhai Enterprises reports consolidated net profit of Rs 0.35 crore in the June 2024 quarter

Net profit of Ambalal Sarabhai Enterprises reported to Rs 0.35 crore in the quarter ended June 2024 as against net loss of Rs 4.87 crore during the previous quarter ended June 2023. Sales rose 12.74% to Rs 40.70 crore in the quarter ended June 2024 as against Rs 36.10 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales40.7036.10 13 OPM %1.18-11.00 - PBDT1.82-3.55 LP PBT0.84-4.60 LP NP0.35-4.87 LP Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Ambalal Sarabhai Enterprises announces board meeting date

Ambalal Sarabhai Enterprises will hold a meeting of the Board of Directors of the Company on 9 August 2024.Powered by Capital Market - Live

3 months agoCapital Market - Live
Ambalal Sarabhai Enterprises के Mohal Sarabhai से खास बातचीत, जानें Company का Future Plan
3 years agoCNBC Awaaz

Cosara Diagnostics gets CDSCO license to manufacture SARAGENE Dengue Test Kit

3 years agoIndia Infoline
KYC में Ambalal Sarabhai Enterprises का Management, Company के नए Plan पर चर्चा | CNBC Awaaz
3 years agoCNBC Awaaz

Ambalal Sarabhai Enterprises consolidated net profit rises 2760.22% in the June 2021 quarter

3 years agoBusiness Standard

Ambalal Sarabhai Enterprises consolidated net profit rises 20.84% in the March 2021 quarter

3 years agoBusiness Standard

Ambalal Sarabhai Enterprises reports standalone net loss of Rs 8.93 crore in the March 2021 quarter

3 years agoBusiness Standard